You are here
Generic Wellbutrin XL Clears FDA Hurdle
August 6, 2013
HAYWARD, Calif. November 28, 2008 – IMPAX Laboratories, Inc. announced that the U.S. Food and Drug Administration (FDA) granted final approval of the Company's Abbreviated New Drug Application (ANDA) for a generic version of Wellbutrin® XL 150 mg Extended-release Tablets on Wednesday, November 26, 2008. GlaxoSmithKline markets Wellbutrin® XL for the management of depression. IMPAX’s Global Pharmaceuticals division launched the product immediately following approval. According to Wolters Kluwer Health, U.S. sales of Wellbutrin® XL 150 mg tablets were approximately $950 million in the 12 months ended September 2008.
Wellbutrin is a trade name of the drug bupropion, which works by slowing the absorption of dopamine and norepinephrine in the synapse between nerve cells.
Source: Impax Laboratories
Scenesse is new treatment for people with rare, painful light sensitivity disease
Humira, Rituxan top list of drugs that added $5.1 billion to nation's health care bill
Lower court rulings cleared the way for generic versions of the MS drug
Maryland man wins lawsuit that alleges that the company's antipsychotic caused his gynecomastia
Antidepressants, ADHD meds are also used to self-poison
Study lists steps that could save close to $300 billion a year
While many victims used THC, the cause remains elusive
Descovy joins Truvada, another Gilead product, in the HIV prophylaxis market
Data show PTC Therapeutics drug preserves lung function